At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 107 enrolled
Drug / intervention
DE-117 Ophthalmic Solutiondrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Multicenter Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution 0.002% in Latanoprost Low/Non-Responder Subjects Diagnosed With Primary Open-Angle Glaucoma or Ocular Hypertension - Spectrum 5 Study
In Brief
A Phase 3 clinical trial evaluating DE-117 Ophthalmic Solution for Primary Open-angle Glaucoma and Ocular Hypertension. Completed, enrolled 107 participants across 32 sites.
Detailed Summary
Santen will evaluate the intraocular pressure (IOP) lowering effect and efficacy of DE-117 ophthalmic solution 0.002% in latanoprost low/non-responder subjects diagnosed with POAG or OHT
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
Enrollment StartSep 2018
First PostedOct 2018
Primary CompletionJan 2022
TodayJul 2026
First PostedOct 5, 2018
Enrollment StartSep 27, 2018
Primary CompletionJan 13, 2022
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 7.7 years ago
Interventions
DE-117 Ophthalmic Solutiondrug
Interventional treatment will be made with DE-117 Ophthalmic Solution 0.002% once daily in the evening for the duration of the 3 month treatment period.